Form 4: Avidity Biosciences CFO Sells Shares to Cover Tax Obligations After RSU Vesting

Avidity Biosciences' Chief Financial Officer, Michael F. MacLean, sold 11,151 shares of common stock to cover tax obligations following the vesting of restricted stock units.

Summary

• Michael F. MacLean, the Chief Financial Officer of Avidity Biosciences, sold 11,151 shares of common stock on December 18, 2024.
• The sale was executed at a weighted-average price of $32.66 per share, with individual transactions ranging from $32.66 to $32.66.
• This sale was not a discretionary trade but was mandated by the company's equity incentive plan to cover tax withholding obligations related to the vesting of 25,000 restricted stock units (RSUs).
• The RSUs vested on December 17, 2024, and were initially granted as performance-based restricted stock units (PSUs) before converting to time-based RSUs on June 17, 2024, after a performance objective was met.
• The CFO's remaining holdings after the transaction are 82,942 shares.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction related to executive compensation. While not inherently positive or negative, it is a standard practice and does not indicate any significant change in the company's outlook.

Positives

• The sale was part of a pre-arranged plan to cover tax obligations, indicating standard practice.
• The vesting of the RSUs suggests the company met certain performance objectives.

Risks

• While not a discretionary sale, large sales by insiders can sometimes be perceived negatively by the market.

Management Comments

• The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell-to-cover' transaction and does not represent a discretionary trade by the Reporting Person.

Industry Context

This type of transaction is common for executives who receive equity compensation, particularly when vesting events trigger tax liabilities. It is a standard practice for companies to offer 'sell-to-cover' options to manage these tax obligations.

Comparison to Industry Standards

• Many biotechnology companies use equity compensation as part of their overall compensation strategy.
• Sell-to-cover transactions are a common mechanism for executives to manage tax liabilities associated with vesting equity awards.
• The number of shares sold and the price are within the typical range for such transactions in the biotech industry.

Stakeholder Impact

• The sale of shares by the CFO may have a minor impact on the stock price, but it is unlikely to be significant given the nature of the transaction.

Key Dates

Keywords

Avidity Biosciences, insider trading, Form 4, stock sale, restricted stock units, RSU, tax obligations, Michael F. MacLean, CFO, equity incentive plan